About Pulmatrix (PULM)

Instrument Summary: Pulmatrix Inc. (PULM) is a biopharmaceutical company that focuses on developing innovative inhaled therapies for the treatment of respiratory diseases and infections. The company's proprietary technology platform, called iSPERSE (inhaled Small Particles Easily Respirable and Emitted), allows for the delivery of therapeutic compounds directly to the lungs, resulting in improved efficacy and reduced systemic side effects. Pulmatrix's lead product candidate is Pulmazole, an inhaled anti-fungal therapy for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. ABPA is a chronic and severe respiratory disorder caused by a hypersensitivity reaction to the fungus Aspergillus fumigatus. Currently, there are no approved inhaled therapies specifically for ABPA.

Pulmatrix's stock price history reflects the volatility often seen in the biopharmaceutical industry. Over the past five years, the stock has experienced significant fluctuations, reaching highs of over $10 per share and lows of under $1 per share. This volatility can be attributed to various factors, including the success or failure of clinical trials, regulatory approval processes, and market acceptance of Pulmatrix's products. Investors in Pulmatrix should be aware of the risks associated with investing in biopharmaceutical companies, including the potential for significant losses if clinical trials do not yield positive results or if regulatory approvals are not obtained.